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Cushing disease (CD) is a rare endocrine disorder caused by
ACTH secretion leading to cortisol excess [1]. Reported
recurrence rates are quite high throughout most of the stu-
dies [2, 3]. Usually, close surveillance after first successful
therapy is recommended [4–6], including both clinical and
biochemical assessment. The Endocrine Society Clinical
Practice Guideline on the treatment of CS recommends to
screen patients for recurrence after recovery of the HPA
axis and after that, annually or if the patient has clinical
symptoms [5]. Low-dose dexamethasone suppression test,
late-night salivary cortisol and cortisol in a 24-h collection
are part of the standard screening approach. Of these tests,
midnight salivary cortisol is the first parameter to become
abnormal in patients with recurrence [7–9].
Currently, there is a level of uncertainty in the diagnosis
of recurrence as on one side, a cyclic biochemical pattern is
not uncommon in recurrent CS [10], which makes it chal-
lenging to confirm suspected recurrence by biochemical
screening. On the other side, physiological forms of
hypercortisolism may also occur in patients who are actu-
ally in remission [11]. Based on this background, we ana-
lyzed prospectively the clinical and biochemical course of
patients with recurrent CD to answer the question, in which
sequence clinical and biochemical parameters recur. Using a
historic retrospective cohort for comparison, we wanted to
answer whether annual follow-up identifies recurrence
earlier.
Materials and methods
Patients, procedures and variables
This study is part of the prospective German Cushing
Registry (founded in 2012). So far, 67 prospectively studied
patients with newly diagnosed overt CD formed the study
cohort. Furthermore, 100 patients with treated CD were
retrospectively included in the registry at variable time
points of their disease. These patients did not receive a
structured annual follow-up assessment. The German
Cushing Registry was approved by the LMU ethics com-
mittee, and all patients gave written informed consent.
Successful surgery was defined as a phase of adrenal
insufficiency post-surgery, requiring glucocorticoid repla-
cement therapy, and a regression of clinical symptoms.
Patients were examined 1, 3, 6 and 12 months after surgery
and annually thereafter (checklist-based clinical examina-
tion, recording of new or worsening comorbidities com-
bined with biochemical testing by 1-mg low-dose
dexamethasone suppression test, urinary free cortisol and
late-night salivary cortisol). Depending on the clinical and
biochemical results, patients are classified as being in
remission or as having suspected recurrence.
Biochemical evaluation
All patients underwent blood samples between 8:00 and
11:00 am in the fasting state. Patients collected late-night
saliva and urine over 24 h at home (one morning urine was
included in the total volume). LDDST was performed after
sampling of urine and saliva. Urinary cortisol was measured
at the central laboratory of our hospital using an automated
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electro-chemiluminescence immunoassay (LIAISON Dia-
Sorin, Saluggia, Italy, reference value <85 µg/24 h, grey
zone 85–115 µg/24 h). Patients receiving glucocorticoid
replacement therapy at time of evaluation paused hydro-
cortisone for 16 h before starting biochemical sampling.
All other laboratory analyses were performed at the
Endocrine Laboratory of the Medizinische Klinik und
Poliklinik IV, LMU Munich. Salivary cortisol, serum cor-
tisol and plasma ACTH were measured using automated
CLIAs, (salivary cortisol: IDS-iSYS, Immunodiagnostic
Systems, Boldon, UK; serum cortisol and plasma ACTH:
LIAISON DiaSorin, Saluggia, Italy), as reported previously
[12]. Normal late-night salivary cortisol is defined as
<1.5 ng/mL (grey zone >1.5 <2.3 ng/mL).
Statistics
For statistical analysis, SPSS 26 was used. Non-parametric
tests were used to test differences between groups. P values
of < 0.05 were considered to indicate statistical significance.
Results
Of the 67 patients, 14 were excluded due to incomplete
data/loss to follow-up. Of the remaining 53 patients, 9 had
persistent disease after first surgery. Nine of the 44 patients
who were in remission after first surgery developed bio-
chemical or clinical abnormalities during a mean follow-up
time of 46 ± 20 month. All nine patients (5 women, 4 men)
suffered from adrenal insufficiency within the first 4 weeks
post surgery (median baseline cortisol: 4.6 (1.0–9.0) µg/dL).
As a general pattern we did not observe clinical signs of
CS without biochemical abnormalities. Compared to bio-
chemical and clinical results at first diagnosis, all variables
were significantly lower at time of recurrence (p= 0.01).
The main symptom in the recurrence group was weight gain
in 56% of patients. Comorbidities were more common at
first diagnosis than in recurrent disease (p= 0.03). Table 1
shows clinical and biochemical variables.
Mean interval time between first diagnosis and diagnosis
of recurrence was 49 months (±22). In six of the nine
patients, biochemical parameters were abnormal before
patients developed signs and symptoms of CS (individual
pattern see Supplementary Fig. 1). In the other three
patients, clinical symptoms and biochemical abnormalities
occurred at the same time. In three of the nine patients, all
three tests turned abnormal at the same time, in the other six
patients, one or two tests turned abnormal first. Treatment at
first diagnosis was surgery in all patients. Patients with
recurrence received medical treatment (n= 3), second
transsphenoidal surgery (n= 1), radiotherapy (n= 1) and
no treatment (n= 4, ‘wait-and-watch’ strategy).
Historic control cohort
Sixteen patients of the historic retrospective cohort had
recurrence of CD. Recurrence was diagnosed significantly
later than in the prospective cohort (mean 8.6 ± 4.8 vs.
4.2 ± 1.6 years of follow-up, p < 0.048). Urinary free corti-
sol was higher and clinical signs and symptoms were more
common and more pronounced (Supplementary Table 1).
All of these patients received a treatment (no ‘watch-and-
wait’ strategy).
Discussion
Regular follow-ups after first successful surgery are
recommended [5, 13, 14] but a unifying consensus on
specific clinical and biochemical testing and follow-up
intervals has not been established so far. Also, recurrence
criteria are not universally agreed on [15].
In our study, we pursued an exploratory approach: as we
observed our patients prospectively, we collected in parallel
complete clinical and biochemical data of patients with CD.
A major finding of our study is that the prospective
assessment identified patients with recurrent CD much
earlier (4 vs. 8 years). Moreover, biochemical activity, the
Cushingoid phenotype and comorbidities were much more
prominent in the latter than in the former.
It is the essence of this approach that patients with
clinical signs of CD always have abnormal biochemical
tests but not the other way round. Therefore, a clinical
approach with focus on signs and symptoms will lead to a
delayed diagnosis of recurrence, compared to annual bio-
chemical screening. However, the early diagnosis resulted
into a watch-and-wait strategy in nearly half of our patients.
Whether this scenario is of advantage for patients or has
negative impact in terms of quality-of-life outcomes cannot
be answered in our study. Other studies suggest to start a
specific treatment early, in analogy to patients with sub-
clinical adrenal CS, in whom hypercortisolism is associated
with increased cardiovascular morbidity and mortality [16].
A study by Carroll et al. emphasized that patients with
recurrence can benefit from early secondary treatments [17].
A theoretical advantage of early diagnosis of recurrence
might lay in a higher flexibility regarding treatment options,
using pasireotide in patients with mild hypercortisolism
[18, 19] or radiotherapy without the need for a bridging
hypercortisolism-directed pharmacotherapy.
Limitations, strengths and outlook
This study has limitations including the monocentric design
and the quite small sample size of patients with recurrence.
This contrasts with its strength, the comprehensively,
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prospective observation of the study cohort. To our
knowledge, there is no other study reporting the course of
recurrence in a similar way. Future studies should especially
focus on the benefits of an early diagnosis or recurrence and
the potential influence on the long-term outcome of patients
with CD.
Table 1 Course of clinical signs, comorbidities and biochemical variables at time of first diagnosis and at time of recurrence (N= 9) of the
prospective Cushing cohort
First diagnosis Recurrence p values
Clinical symptoms (frequency)
Weight gain 100% 56%
Buffalo hump 89% 11%
Moon face 78% None
Bruises 68% None
Plethora 67% None
Muscle weakness 67% 11%
Loss of libido 67% None
Odema 56% 11%
Thin skin 44% 22%
Hair loss 44% None
Hirsutism 22% None
Acne 11% None
Mean number of symptoms 7.0 ± 3.4 1.1 ± 1.2 p= 0.01
Biochemical screening (median and quartiles)
9 am serum cortisol (µg/dL)
reference interval: 4–24 µg/dL
38 (20–45) 10 (8–11) p= 0.01
ACTH (pg/mL)
reference interval: 10–50 pg/ml
96 (50–109) 34 (16–47) p= 0.02
LDDST (µg/dL)
reference interval: <2
18 (15–27) 4 (3–6) p= 0.01
Late-night salivary cortisol (ng/mL)
reference interval: <1.5 nmol/L
12 (5–22) 4 (2–5) p= 0.01
UFC (µg/24 h)
reference interval: <85 µg/die
748 (394–1220) 111 (70–253) p= 0.01
Clinical examination (median and quartiles)
BMI 27 (23–32) 24 (23–28) p= 0.2
Hip (circumference in cm) 97 (94–101) 100 (98–102) p= 0.5
Waist (circumference in cm) 110 (86–115) 97 (76–100) p= 0.04
Upper arm (circumference in cm) 27 (26–30) 27 (26–30) p= 0.6
Waist-hip-ratio 1.0 (0.97–1.15) 0.96 (0.80–0.97) p= 0.03
Waist-height-ratio 0.59 (0.51–0.71) 0.51 (0.44–0.61) p= 0.05
Waist-arm-ratio 3.6 (3.5–4.1) 3.2 (2.9–3.3) p= 0.03
Blood pressure (systolic in mmHg) 149 (140–168) 129 (123–133) p= 0.07
Blood pressure (diastolic in mmHg) 99 (87–111) 84 (78–89) p= 0.06
Comorbidities (frequencies)
Hypertension 100% 33%




Number of comorbidities 2.7 ± 0.9 1.4 ± 0.9 p= 0.03
Bold numbers indicate significance
UFC urinary free cortisol, LDDST 1-mg low-dose dexamethasone suppression test, TSS transsphenoidal surgery, LNSC late-night salivary cortisol
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